The goal of anti-angiogenic therapy is to limit the blood flow to tumour tissue by delivering anti-angiogenic drugs to reduce tumour growth and metastasis.21 The VEGF protein was first identified in 1989, and its role in angiogenesis was discovered.22,23 Having a weight of 40–45 kD, VEGF is a dimeric protein rich in cysteine that is highly conserved in mammals. This evidence concerns the gene VEGFA and neoplasm.